


COAPT: Transcatheter Mitral Valve Repair in Patients With Heart Failure

Multicenter, randomised, controlled, parallel group trial




AMERICAN COLLEGE of CARDIOLOGY

Objective: To assess the utility of transcatheter mitral valve repair with the MitraClip device in symptomatic patients with heart failure (HF) and moderate-to-severe or severe mitral regurgitation



614 Symptomatic patients with HF and moderate-to-severe or severe mitral regurgitation were randomized to



Primary Outcome

35.8% Hospitalizations for HF within 24 months per patient-year
HR 0.53; 95% CI 0.40–0.70;
 $P < 0.001$ **67.9%**

Secondary Outcome

29.1% All-cause mortality
HR 0.62; 95% CI 0.46–0.82;
 $P < 0.001$ **46.1%**

Among patients with symptomatic HF and moderate-to-severe or severe mitral regurgitation, transcatheter mitral valve repair resulted in a lower rate of hospitalization for HF and lower all-cause mortality within 24 months compared with medical therapy only